It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Severe neurological symptoms are associated with Coronavirus disease 2019 (COVID-19). However, the morphologic features, pathological nature and their potential mechanisms in patient brains have not been revealed despite evidence of neurotropic infection. In this study, neuropathological damages and infiltrating inflammatory cells were quantitatively evaluated by immunohistochemical staining, ultrastructural examination under electron microscopy, and an image threshold method, in postmortem brains from nine critically ill COVID-19 patients and nine age-matched cadavers of healthy individuals. Differentially expressed proteins were identified by quantitative proteomic assays. Histopathological findings included neurophagocytosis, microglia nodules, satellite phenomena, extensive edema, focal hemorrhage, and infarction, as well as infiltrating mononuclear cells. Immunostaining of COVID-19 brains revealed extensive activation of both microglia and astrocytes, severe damage of the blood–brain barrier (BBB) and various degrees of perivascular infiltration by predominantly CD14+/CD16+/CD141+/CCR7+/CD11c+ monocytes and occasionally CD4+/CD8+ T lymphocytes. Quantitative proteomic assays combined with bioinformatics analysis identified upregulated proteins predominantly involved in immune responses, autophagy and cellular metabolism in COVID-19 patient brains compared with control brains. Proteins involved in brain development, neuroprotection, and extracellular matrix proteins of the basement membrane were downregulated, potentially caused by the activation of transforming growth factor β receptor and vascular endothelial growth factor signaling pathways. Thus, our results define histopathological and molecular profiles of COVID-19-associated monocytic encephalitis (CAME) and suggest potential therapeutic targets.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 the First Affiliated Hospital of University of Science & Technology of China, Department of Pathology, Hefei, P.R. China (GRID:grid.411395.b) (ISNI:0000 0004 1757 0085); Ministry of Education of China, Institute of Pathology & Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), and Key Laboratory of Tumor Immunopathology, Chongqing, P.R. China (GRID:grid.416208.9) (ISNI:0000 0004 1757 2259); Shanghai Jiaotong University, 200025, Department of Pathology, Ruijin Hospital, School of Medicine, Shanghai, P.R. China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293)
2 Ministry of Education of China, Institute of Pathology & Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), and Key Laboratory of Tumor Immunopathology, Chongqing, P.R. China (GRID:grid.416208.9) (ISNI:0000 0004 1757 2259)
3 Peking Union Medical College and Chinese Academy of Medical Sciences, Stem Cell and Regenerative Medicine Lab, Department of Medical Science Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Translational Medicine Center, Peking Union Medical College Hospital, Beijing, P.R. China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839)
4 Army Medical University (Third Military Medical University), Department of Anatomy, Key Laboratory for Biomechanics and Tissue Engineering of Chongqing, State Key Laboratory of Trauma, Burn and Combined injury, Chongqing, P.R. China (GRID:grid.410570.7) (ISNI:0000 0004 1760 6682)
5 Wuhan Jinyintan Hospital (Wuhan Hospital for Infectious Diseases), Wuhan, P.R. China (GRID:grid.507952.c) (ISNI:0000 0004 1764 577X)
6 Peking Union Medical College and Chinese Academy of Medical Sciences, Department of Cardiology, Peking Union Medical College Hospital, Beijing, P.R. China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839)
7 the First Affiliated Hospital of University of Science & Technology of China, Department of Pathology, Hefei, P.R. China (GRID:grid.411395.b) (ISNI:0000 0004 1757 0085); Ministry of Education of China, Institute of Pathology & Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), and Key Laboratory of Tumor Immunopathology, Chongqing, P.R. China (GRID:grid.416208.9) (ISNI:0000 0004 1757 2259)